Browse the evidence

Coadministration of tirzepatide and SGLT2 inhibitors in Type 1 Diabetes Mellitus patients significantly increases the risk of severe euglycemic diabetic ketoacidosis (euDKA), potentially requiring mechanical ventilation.

If you have Type 1 Diabetes, do not take Tirzepatide or SGLT2 inhibitors together without extreme caution and specialist oversight. Monitor ketones daily, especially if you feel nauseous or vomit, as blood sugar may remain normal while dangerous acidosis builds up.

Timing of protein ingestion (before vs. after resistance training) does not significantly affect total body lean mass gains.

You do not need to rush to drink protein immediately after your workout. As long as you consume your protein within a few hours before or after training, your muscle growth will be the same. Focus on getting enough total protein throughout the day rather than stressing about the exact timing.

Timing of protein ingestion does not significantly affect upper body (chest press) strength gains.

For upper body exercises like chest press, it does not matter if you drink your protein before or after your workout. Your strength gains will be the same. Focus on getting enough total protein throughout the day.

High-volume static stretching is a viable therapeutic alternative or supplement for counteracting immobilization-induced muscle atrophy in patients who are bedridden, post-surgery, or have mobility restrictions.

If you are recovering from surgery or an injury and cannot lift weights, use a stretching device or manual stretching for 30 minutes to 2 hours daily. This can help prevent muscle loss during immobilization. Consult your doctor before starting.

Proximity to failure (4-6 RIR vs 1-3 RIR vs 0 RIR) does not significantly affect muscle hypertrophy (muscle thickness) in trained men over an 8-week period.

For muscle growth, it does not matter much whether you train to failure or stop with 1-3 reps left. Both approaches can yield similar hypertrophy. Focus on consistency and progressive overload rather than chasing failure on every set.

Natural peptides (BRP, BPC-157, MOTS-c) offer a safer, more metabolically specific alternative to semaglutide for obesity management by preserving lean mass and avoiding severe gastrointestinal side effects.

Natural peptides like BRP, BPC-157, and MOTS-c are emerging as potential alternatives to semaglutide, offering weight loss with better preservation of muscle mass and fewer gastrointestinal side effects. However, current evidence is limited to animal studies. Patients should consult healthcare providers regarding the safety, dosage, and regulatory status of these peptides, as they are not yet standard FDA-approved treatments for obesity.

Acute administration of GLP-1 receptor agonists reduces brain reactivity (BOLD response) to food-related cues in reward and salience regions, whereas long-term administration effects are inconsistent or attenuate over time.

GLP-1 medications appear to reduce the brain's intense reaction to food cues, particularly when taken acutely. However, this neural dampening may not persist or may vary significantly with long-term use. The evidence is currently limited and inconsistent, so while the mechanism suggests reduced craving, individual responses to long-term cue reactivity reduction are not guaranteed.

Neurokinin 2 receptor (NK2R) activation reduces appetite and body weight in mice without the gastrointestinal side effects associated with GLP-1 based treatments.

Research is exploring new drugs that target Neurokinin 2 Receptors (NK2R) to suppress appetite without causing the nausea common with current GLP-1 drugs. These are currently only proven effective in mice, so they are not yet available for human use.

Tirzepatide can cause direct drug-induced liver injury (hepatitis) independent of gallbladder disease, characterized by elevated liver enzymes and bilirubin that normalize upon discontinuation.

If you are taking Tirzepatide and experience symptoms like jaundice, dark urine, or right-sided abdominal pain, seek medical attention immediately. Your doctor should check liver enzymes. If levels are elevated, stopping the drug typically leads to full recovery within a month, but this requires prompt medical intervention and monitoring.

Tirzepatide therapy can cause euglycaemic ketoacidosis in non-diabetic patients, particularly when initiated via online prescribing without rigorous monitoring, due to starvation induced by gastrointestinal side effects.

If you are taking tirzepatide (Mounjaro) for weight loss, especially through an online service, be aware that you can develop a dangerous condition called euglycaemic ketoacidosis. This means your blood becomes acidic due to ketones, even if your blood sugar stays normal. Watch for symptoms like nausea, vomiting, abdominal pain, and fatigue. If you feel unwell, check your ketones if possible and seek medical attention immediately. Do not ignore gastrointestinal side effects as they can lead to starvation and acidosis.

Tirzepatide use is associated with a probable risk of acute pancreatitis, characterized by a strong temporal correlation between drug initiation and symptom onset, and clinical resolution upon discontinuation.

If you are taking tirzepatide and develop severe, persistent upper abdominal pain, nausea, or vomiting, stop the medication immediately and seek medical attention. Do not assume the pain is just from gallstones or indigestion, especially if it started shortly after beginning the drug. Early discontinuation can prevent severe complications.

Modifying the physical structure of beef (minced vs. steak) while keeping nutrient composition identical does not significantly alter muscle protein synthesis (MPS) rates, but it does significantly improve whole-body net protein balance by enhancing digestion and absorption kinetics.

If you are eating enough protein (around 26g+ per meal) and engaging in resistance training, the physical form of your meat (minced vs. steak) likely does not change how much muscle you build directly. However, minced meat may be easier to digest and absorb, leading to better overall protein retention in the body, which might be beneficial for older adults or those with chewing difficulties.

Higher carbohydrate intake does not independently enhance resistance training-induced muscle hypertrophy when protein and energy intake are controlled.

You do not need to eat high carbohydrates to maximize muscle growth. As long as you are consuming enough protein and total calories (energy surplus for growth), you can choose your carbohydrate intake based on personal preference, performance needs, or digestive comfort without negatively impacting your muscle gains. Low-carb diets are not inherently inferior for hypertrophy if energy and protein are adequate.

Bariatric arterial embolization (BAE) produces modest, transient weight loss (mean 7.0% at 4-5 months, 4.2% at 12 months) in patients with BMI ≥30 who have failed nonoperative management and are ineligible or unwilling to undergo metabolic-bariatric surgery.

If you have obesity (BMI ≥30) and haven't been able to lose weight through diet, exercise, or standard medications, and you are not a candidate for or do not want surgery, BAE might be an option. It involves a minimally invasive procedure to block blood flow to part of the stomach, which reduces hunger hormones. Expect modest weight loss (around 4-7%) over the first year, but it requires ongoing support from a weight management program. It is not a standalone fix and results vary significantly between individuals.

GLP-1 receptor agonists (GLP-1RAs) may indirectly improve autoimmune thyroid disease (AITD) outcomes by reducing systemic inflammation, improving insulin sensitivity, and modulating the gut-thyroid axis, rather than through direct thyroidal effects.

If you have thyroid autoimmunity and are considering GLP-1RAs for weight or diabetes, expect that your thyroid medication doses may need adjustment as you lose weight. The drug likely helps your thyroid health indirectly by lowering body-wide inflammation and improving metabolic health, rather than directly attacking thyroid antibodies. There is no strong evidence yet that it cures thyroid disease, but it is generally safe regarding thyroid cancer risk in humans. Work closely with your endocrinologist to monitor your thyroid levels during weight loss.

Women with non-diabetic obesity experience greater cardiovascular benefits from GLP-1 RAs, particularly regarding heart failure hospitalization and stroke reduction, compared to men.

Women with obesity may derive even greater heart protection from GLP-1 medications than men, especially regarding heart failure prevention. This is particularly true for postmenopausal women who are at higher risk for heart failure with preserved ejection fraction (HFpEF). Discussing your specific heart failure risk with your provider is crucial.

State-of-the-art anti-obesity medications (AOMs) like GLP-1 analogues are highly effective appetite suppressants but require continuous use, as discontinuation leads to inevitable weight regain.

Understand that obesity medications like Semaglutide or Tirzepatide are long-term treatments. Stopping them will likely lead to weight regain. Plan for continuous use as part of your long-term health strategy.

Phytotherapeutic agents (e.g., Green Tea, Nigella Sativa, Bofu Tsusho San) produce statistically significant but clinically less relevant weight loss compared to modern AOMs.

Herbal supplements like Green Tea or Black Seed may help with modest weight loss, but they are not as effective as prescription medications like Semaglutide or Tirzepatide. Manage your expectations accordingly.

Current randomized controlled trial evidence does not demonstrate a statistically significant increase in thyroid cancer risk with the use of incretin-based therapies (GLP-1RAs and dual GIP/GLP-1RAs).

Current high-quality randomized trial data does not support a claim that GLP-1 or GIP/GLP-1 drugs cause thyroid cancer in the general population. However, the evidence is very low certainty because these trials are too short and too small to rule out a rare, long-term risk. Clinicians should continue prescribing these drugs for their proven benefits while adhering to the FDA boxed warning for patients with a specific family history of medullary thyroid cancer.

Preoperative use of GLP-1 receptor agonists is associated with reduced rates of periprosthetic joint infection (PJI) and hospital readmission in patients undergoing total hip and knee arthroplasty, particularly among those with diabetes or morbid obesity.

If you are taking a GLP-1 RA (like Ozempic or Wegovy) before hip or knee replacement surgery, current evidence suggests it may lower your risk of joint infection and hospital readmission, especially if you have diabetes or obesity. However, because these drugs cause rapid weight loss, your surgical team must carefully monitor your nutritional status (e.g., albumin levels) to ensure you are not malnourished, which could increase complication risks. Do not stop the medication without consulting your surgeon, as the net benefit appears positive in many cases, but close monitoring is essential.

Epitalon, a tetrapeptide, extends cellular lifespan by activating telomerase and lengthening telomeres, while also modulating pineal gland function to restore melatonin synthesis.

Epitalon is an investigational peptide that may extend cellular lifespan by activating telomerase and restoring melatonin production. While animal studies show promising lifespan extension, human data is limited to small studies without long-term safety validation. It is not FDA-approved for anti-aging.

BPC-157 and TB-500 enhance tissue repair and angiogenesis in aged tissues, showing promise in small pilot studies for chronic pain and wound healing.

BPC-157 and TB-500 are peptides that may help heal tissues, tendons, and muscles by promoting blood vessel growth and reducing inflammation. Small studies suggest they can relieve chronic pain and heal wounds, but they are not FDA-approved for these uses, and long-term safety is unknown.

Semax enhances neuroplasticity and cognitive function in aging by upregulating BDNF and modulating neurotransmitter systems, showing benefits in stroke recovery and cognitive decline.

Semax is a peptide that may improve brain health by increasing BDNF, a key factor in neuroplasticity. Russian studies suggest it can help stroke recovery and cognitive function, but it is not FDA-approved for these uses, and independent Western validation is lacking.

Ultrasonography is recommended as the initial screening tool for hepatic steatosis in Latin America.

Practitioners should use ultrasonography for initial screening of MASLD patients.